More on LLY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1160.95 |
|
|||
| Open | $1165.00 | ||||
| 52 Wk High | $88.16 | ||||
| 52 Wk Low | $67.88 | ||||
| Day High | $1169.99 | ||||
| Day Low | $1132.81 | ||||
| P/E | 262.27 | ||||
| EPS | $4.32 | ||||
| Volume | 2,437,568 | ||||
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- Leerink highlights drug demand rebound after Memorial Day
- Form 4 ELI LILLY & Co For: Jun 10 Filed by: Yuffa Ilya
- Form 144 ELI LILLY & Co Filed by: Yuffa Ilya
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
- FDA approves Lilly's EBGLYSS for eight-week dosing in atopic dermatitis
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
- Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
Entities mentioned with LLY
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- Dividend | View Related Stories »
- Show More...
